Objective: To evaluate the measurement of 153Sm-EDTMP Bone uptake rate with whole-body scintigraphy and analyze the relationship between bone uptake rate and therapeutic effect.
Methods: 66 patients with bony metastases were examined with whole-body scintigraphy 10 minutes and 6 hours after the administration of 153Sm-EDTMP, and then bone uptake rate was calculated.
Results: The bone uptake rate in 66 patients ranged from 31.9% to 86.6%, (mean 56.0%). The patients with higher bone uptake rate had better overall therapeutic effect. According to the bone uptake rate calculated by whole-body scintigraphy, the therapy activity administered within the limit of bone marrow absorbed dose of 1400 mGy in these patients was 1.40-2.27GBq (mean 1.90 GBq).
Conclusion: The present authors have developed a whole-body scintigraphic technique which is simple and reliable in calculating prospectively a safe and effective dose of 153Sm-EDTMP for palliating the patient's painful bone metastases without myelotoxicity.